OncoMatch/Clinical Trials/NCT05776524
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
Is NCT05776524 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nab paclitaxel and Gemcitabine for pancreatic cancer.
Treatment: Nab paclitaxel · Gemcitabine · TheraBionic — The objective of this research is to find out what effects (good and bad), the combination of gemcitabine and nab-paclitaxel therapy (GEM-ABR for the rest of the document), standard chemotherapy for pancreatic cancer, and the TheraBionic device has on participants' condition.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Excluded: Stage LOCALIZED RESECTABLE, III
Metastatic disease required
newly diagnosed untreated biopsy proven metastatic adenocarcinoma of the pancreas
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: FOLFIRINOX in adjuvant or neoadjuvant setting allowed
Patients treated with any chemotherapy in metastatic setting and/or who had chemotherapy with gemcitabine and/or nab-paclitaxel within six months prior to entering the study in the adjuvant or neo-adjuvant setting are excluded. Patients who have had chemotherapy with FOLFIRINOX prior to entering the study in the adjuvant or neo-adjuvant setting can be enrolled into the study.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Hemoglobin ≥ 7 g/dL (transfusion allowed to meet criteria)
Kidney function
Creatinine ≤ 1.5 X institutional upper limit of normal OR CrCL > 50
Liver function
Total bilirubin ≤ 1.5 X institutional upper limit of normal; AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal (≤ 5 x ULN, if liver metastasis)
Patients must have organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 7 g/dL (transfusion allowed to meet criteria). Total bilirubin ≤ 1.5 X institutional upper limit of normal AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal (≤ 5 x ULN, if liver metastasis) Creatinine ≤ 1.5 X institutional upper limit of normal Or CrCL > 50
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05776524 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages